×

Mylan CEO was not unfairly targeted: Analyst

7:57 PM ET Wed, 21 Sept 2016

In the past four years, Mylan has raised the EpiPen's price far more than the increase in the cost of goods, says Rodman & Renshaw's Raghuram Selvaraju.